In partnership with
January 5, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition runs through Washington’s new split screen: a White House pressing Schedule III forward, congressional Republicans raising the political cost, and Republican attorneys general positioning for a court fight that could freeze the effective date. The tax story stays hypothetical until that date holds, and the hemp definition rewrite shows how fast a must-pass bill can redraw the map.
Today’s edition is supported by 1440 Media, THC Group, and The Hybrid podcast. To sponsor Policy, Decoded and reach the executives, investors, and policymakers who read this briefing, reply to this email and we will send details.
⚖️ Effective Date Pressure
🌾 Hemp Cliff Politics
🏛️ GOP Split Screen
The process matters.
Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: President Trump directed DOJ to finish the rulemaking process to move marijuana to Schedule III and framed the move around medical use, research, and access to certain CBD products. Congressional Republicans broke ranks publicly, warning about youth exposure and public safety and treating rescheduling as a cultural line they still want to hold. The party tightened the hemp definition in a must-pass bill, and then the White House turned around and asked Congress to reopen it. That sequence exposed a real split inside the GOP. Republican attorneys general signaled coordinated opposition quickly and used language that fits a courtroom more than a negotiating table. Advocacy groups on the prohibition side are preparing litigation the moment a final rule publishes, including hiring Bill Barr, a sign they want the effective date tied up before anyone can plan around it. This is the predictable rhythm of modern Washington. The White House moves with urgency and critics search for the levers that slow implementation or stop it altogether. Voters are watching every step.
💡 Why It Matters: Congress cannot snap its fingers and stop rescheduling. It can still make the path politically miserable, though. Oversight turns into a slow leak: letters, subpoenas, hearings, staff questions, and agency lawyers getting pulled into meetings where the safest answer is to take more time. Funding is the other pressure point. Riders get floated in must-pass bills because that is where Washington hides its sharp objects, and the hemp industry already knows how quickly a late-night rewrite can become law. The risk of presidential veto still matters, so the clean legislative kill shot stays unlikely, if they could even get the votes. So watch the courts and state attorneys general. A final rule gives opponents a target and a timeline, and the first serious move will be a stay aimed at the effective date. Freeze that date and 280E relief stays trapped on PowerPoints. Boards hesitate, lenders wait, and the market behaves like the old rules still run the place (because they do). Republican attorneys general have the strongest incentive to bring that case, especially the ones building a brand for the next job. Governor? US Senator?
🧠 THC Group Take: Marijuana reform has historically been cast as a progressive push with libertarian roots. Real life ruined that storyline. Republican voters have been approving medical access in red states for years, and many of the same families who worry about youth use also have a parent with cancer, a child with seizures, or a veteran in the house who wants relief that feels safer than pills. Trump saw a vacuum Democrats helped create by campaigning on reform while letting federal action drown in process, and he grabbed the one lever that can move without a vote. Congressional Republicans now sit in an uncomfortable place. They can oppose loudly to satisfy the law-and-order base and still hope the machinery keeps moving because it gives business a tax story and gives the White House ownership of any backlash. Attorneys general do not have to live with that ambiguity. They can file a lawsuit, call it public safety, and run on it for the next job.
The politics are shifting toward a broad middle that wants adult rules, clear age boundaries, and less hypocrisy in federal law. That middle also wants fewer surprises, and the current setup delivers surprises by design. A party prepared to own this issue would write a framework that protects disciplined medical access, draws hard lines on youth exposure, and crushes the candy knockoffs that keep producing the worst headlines. Until someone does that, rescheduling stays a live fight and cannabis remains popular, profitable, and politically unsettled.
Fast-moving headlines, flagged for what matters.
President Trump’s push to expedite Schedule III is drawing open resistance from senior House and Senate Republicans, a rare split on a lane that hits taxes, research, and culture. Speaker Mike Johnson urged Trump to pause, and top Senate Republicans warned rescheduling would worsen addiction risk, child exposure, and public safety harms. Health Secretary Robert F. Kennedy Jr. backed the shift and framed cannabis compounds as medically meaningful, giving the White House a high-profile ally who aggravates the law-and-order wing. Trump paired the rescheduling push with a Medicare pilot for certain CBD products and a request that Congress revisit the tightened hemp definition passed in November. The rulemaking may keep moving, but the next phase will be shaped by oversight pressure and must-pass leverage, not quiet consensus. (POLITICO)
A new federal hemp definition is poised to make most hemp-derived THC products illegal in November unless Congress intervenes. The change would cap total THC per container at 0.4 milligrams and set a 0.3 percent limit, a threshold processors say collapses full-spectrum formulations and destabilizes extraction economics. Advocates argue cannabinoid extraction is the revenue engine for many farms today, and a sudden cliff forces shutdowns before fiber and seed markets can absorb acreage. The lane for a fix runs through Congress revisiting the definition and building a finished-product framework that protects disciplined low-dose ingestibles while closing the door on youth-attractive formats. Spring planting decisions will be made under a legal cloud that farmers cannot hedge with good intentions. (KCUR; Harvest Public Media)
A federal appeals court held the dormant Commerce Clause does not apply to state cannabis licensing because marijuana remains illegal at the federal level. The Ninth Circuit ruling keeps residency-favoring licensing schemes alive in its jurisdiction and sharpens a split among courts over whether states can wall off markets from out-of-state applicants. That split reshapes deal timing, forum strategy, and how states draft ownership and control rules. Regulators keep more room to defend local participation without rewriting programs under pressure. Capital strategy stays trapped inside state lines until federal law changes the premise. (Bloomberg Law)
Florida Attorney General James Uthmeier, the Florida Chamber of Commerce, and Associated Industries Florida filed briefs urging the Florida Supreme Court to reject the latest adult-use initiative. The court review turns on single-subject limits and whether the ballot title and summary are clear enough for voters. Smart & Safe Florida still faces a February 1st signature deadline, with oral argument set for February 5th. The consequence is resource allocation, since litigation consumes oxygen while qualification work still has to happen at full speed. If the court narrows the summary or rejects it outright, the campaign calendar collapses overnight. (Florida Politics)
Tennessee’s leading Republican contenders for governor are distancing themselves from President Trump on cannabis even after his December executive order pushed federal agencies to move the Schedule III process forward. U.S. Sen. Marsha Blackburn and U.S. Rep. John Rose aligned with GOP letters urging Trump to reverse course, framing rescheduling as a public safety and youth exposure issue. The posture matters because both are competing to succeed Gov. Bill Lee and cannabis is an easy primary litmus test. The split signals how thin the political runway remains for any Tennessee medical cannabis push even with federal momentum shifting. In state politics, rescheduling will be used as a reason to police the perimeter, not open the gates. (State Affairs Pro)
A new account frames Trulieve CEO Kim Rivers as a major advocate in the push that preceded President Trump’s December 18th executive order directing DOJ to complete the Schedule III rulemaking process. The reporting ties the effort to fundraising and access, alongside public arguments about research and 280E parity for regulated operators. The political consequence is scrutiny risk, since rescheduling becomes easier to attack as donor-driven rather than process-driven. That scrutiny can travel into hearings, litigation posture, and congressional oversight as the rulemaking advances. Every procedural step now comes with a narrative fight attached. (Tallahassee Reports)
THC gummies, tinctures, vapes, and low-dose beverages are spreading through convenience stores and the compliance picture is getting messier by the week. Retailers describe a patchwork of state and local rules, with products that can sit on shelves today and become an enforcement problem tomorrow. Reporting citing NielsenIQ shows the category shifting toward beverages, with 10 milligram cans accelerating quickly. Merchandising and labeling discipline is becoming the differentiator, with successful stores separating THC from alcohol lookalikes, controlling access, and using clear shelf and cooler cues. The next crackdowns will start where confusion is easiest to photograph and hardest to defend, at the cooler door and the checkout line. (Convenience Store News)
Dry January is pushing more consumers to swap alcohol for low dose cannabis beverages and edibles, with brands and retailers describing a January spike that carries into the rest of the year. The piece ties the shift to a longer decline in alcohol use, including Gallup data showing fewer adults drinking and sharper drop-off among Gen Z. Producers pitch low sugar, fewer hangovers, and a familiar social ritual, while retailers frame THC as adjacent to nonalcoholic and functional beverages that serve different roles. The regulatory fault line stays central, with companies acknowledging a state-by-state patchwork and a federal framework that keeps mainstream players cautious. The companies that keep winning will be the ones that treat age control and labeling as product features, not compliance chores. (The Drinks Business)
Alcohol industry veterans are pushing deeper into hemp-derived THC with Highpour, positioning it as a cocktail-program format built for familiar distribution lanes. The lineup includes a 750ml bottle intended for mixed-service and canned offerings from 2.5mg up to 10mg, paired with a 21+ posture. The strategic bet is that on-premise adoption and adult-oriented presentation can keep hemp THC away from the convenience-store gray zone that triggers backlash. The policy risk remains structural: a federal hemp definition fight and a state map that can tighten overnight. If the category leans into cocktail aesthetics, regulators will respond by drilling into serving-size clarity and point-of-sale separation. (BevNET)
Massachusetts flower pricing keeps sliding toward the floor, with state data showing the adult-use market settling into late 2025 at roughly four dollars per gram territory. Retailers are discounting harder to hold traffic in a saturated footprint and the pressure is spilling upstream into wholesale terms and cultivation margins. Consumers see cheap eighths and constant promotions, while licensees carry a fixed cost base that does not move with the menu price. The next wave of exits will come through consolidation, distressed asset sales, and brands forced into survival math. Regulators will feel this in the form of late payments, deferred maintenance, and compliance fatigue. (MassLive)
Oregon’s 2025 market data keeps pointing to steady demand and thinner margins driven by oversupply and low prices. Reporting based on OLCC dashboards shows 2025 sales running below 2024 on a year-to-date basis even as discount pricing holds. Lower topline can still mean strong unit movement, with value continuing to migrate away from growers and toward the retail shelf. Smaller operators with limited runway will be the first to lose bargaining power in wholesale negotiations. The market will not announce the shakeout, it will invoice it. (Portland Business Journal)
Fluent closed a $12.5 million cash sale of its Pennsylvania operations to HIVE Holdings effective December 31st. The company said it used the proceeds to pay down debt and concentrate resources in markets it views as more strategic. Management framed the divestiture as aligned with rescheduling momentum and the prospect of 280E relief. The bigger read is capital discipline: marginal footprints are becoming the first assets to get sold, not the last ones defended. Buyers with cash and clean structures will keep setting the price for everyone else. (Cannabis Business Times)
A New Jersey appeals court ruled a lawsuit from Hoboken medical cannabis business Nature’s Touch can continue, keeping claims of municipal malfeasance in play. The suit alleges then Mayor Ravi Bhalla blocked the dispensary from opening as part of an improper arrangement tied to Jersey City Mayor Steve Fulop, including alleged legal services for Bhalla’s law firm. It also claims Fulop’s wife held a stake in a competing Hoboken cannabis business. The appellate decision turned on a filing deadline issue, not the truth of the allegations. Municipal cannabis decisions will keep getting litigated like procurement fights, because that is what they resemble when the stakes are high. (POLITICO Pro)
Wayne State University has begun studies testing cannabis as a potential therapy for veterans with PTSD and depression, backed by Michigan research grant funding. The lead clinical work is structured as randomized, controlled trials designed to measure symptom change, safety, and functional outcomes over a defined treatment period with follow-up. The research is landing in a vacuum where many veterans already self-direct use while federal systems still cite limited evidence and real risks around dependence and symptom persistence. High-quality trial data could shape clinical standards, state program guardrails, and how rescheduling is argued in public. Once real outcomes data exists, advocacy claims start getting cross-examined. (Wayne State University)
Thailand’s public health minister says more than 7,000 cannabis shops effectively closed in 2025 after license expirations and a sharp drop in renewals. Cabinet approved a draft regulation that narrows who can sell cannabis to four facility types, including medical facilities and pharmacies, and places dispensing under doctor oversight. Existing licenses remain valid until they expire, but renewals and new applications would have to meet the new criteria once the regulation takes effect. The ministry is also adding operational requirements around location rights, odor control, storage standards, and trained on-duty personnel. The retail era is shrinking by administrative attrition rather than dramatic raids. (The Nation Thailand)
The UAE issued a federal decree in December allowing the medical use of industrial hemp under strict guardrails. The rule permits medical products containing hemp compounds and hemp-derived raw materials, paired with testing to meet THC limits. It bans personal or recreational use and blocks veterinary, food, and smoking products derived from hemp, with dietary supplements prohibited as well. Cultivation and seed import and export will run through licensing and secure designated areas. This is a medical channel decision that keeps consumer retail firmly out of bounds. (The National)
From the hearing room to the comment section — we’re watching it all.
🗓️ Dry January content is now openly steering consumers toward hemp-derived THC as an alcohol substitute, and it is doing it with a loose claim that the category is federally legal. That framing collapses the line between disciplined, low-dose, age-gated beverages and higher-risk formats that states are actively trying to push out of convenience-style retail. The consequence is predictable: louder marketing invites faster crackdowns, and the brands that want a durable lane will win on 21+ controls, clear THC labeling, conservative dosing, and retail placement that does not confuse the buyer. (Cannabis Now)
🌴 San Diego’s cannabis scene keeps showing what a mature market looks like when it still has ambition: product innovation, tech-enabled access, and a growing expectation that brands prove quality through testing and consumer education. The city’s equity posture also matters because it frames who gets to participate as the market consolidates, and it gives regulators a live test case for whether social repair can sit beside real competition. (NugMag)
🧬 Tissue culture is moving from a niche propagation tool to a strategic advantage for companies that need clean plant stock, consistent expression, and the ability to scale without dragging pests and pathogens across facilities or borders. As global markets tighten import rules and buyers demand uniformity, genetics teams that can document lineage, validate health status, and reproduce elite material reliably will hold leverage in licensing deals, international expansion, and brand consistency. (Cannabis Industry Journal)
🐶 A large observational dataset tied long-term CBD supplement use in dogs to a decline in the intensity of aggressive behavior over time, while other anxiety-linked behaviors did not show the same shift. The evidence sits in correlation land, built on owner reports and missing clean dosing and product controls, so it is a credibility nudge for further study, not a green light for backyard behavior medicine. (Frontiers in Veterinary Science)